Tripartite Agreement In Clinical Research

Primary Care mCTA aims to simplify and thus accelerate the process of registering and initiating pharmaceutical and biopharmaceutical clinical trials in primary care patients. The intention is for the primary care mCTA system to be used in a routine manner without modification by all pharmaceutical and biopharmaceutical industrial sponsors of clinical research, in which NHS patients are recruited into primary care. In such cases, no further legal review is required, saving money and time. An important benefit of any clinical trial is the ability to use the results and research to secure future funding. Nationally approved standard location agreements help speed up the contracting process of industry-sponsored studies carried out in the NHS by creating the need for site-by-site verifications and local legal agreements.